MX2021011039A - Vectores de adn no virales y usos de estos para expresar agentes terapéuticos con fviii. - Google Patents

Vectores de adn no virales y usos de estos para expresar agentes terapéuticos con fviii.

Info

Publication number
MX2021011039A
MX2021011039A MX2021011039A MX2021011039A MX2021011039A MX 2021011039 A MX2021011039 A MX 2021011039A MX 2021011039 A MX2021011039 A MX 2021011039A MX 2021011039 A MX2021011039 A MX 2021011039A MX 2021011039 A MX2021011039 A MX 2021011039A
Authority
MX
Mexico
Prior art keywords
cedna vectors
fviii protein
expression
viral dna
vivo
Prior art date
Application number
MX2021011039A
Other languages
English (en)
Inventor
Phillip Samayoa
Douglas Anthony Kerr
Debra Klatte
Nathaniel Silver
Original Assignee
Generation Bio Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Generation Bio Co filed Critical Generation Bio Co
Publication of MX2021011039A publication Critical patent/MX2021011039A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2820/00—Vectors comprising a special origin of replication system
    • C12N2820/60—Vectors comprising a special origin of replication system from viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La solicitud describe vectores de ceADN que tienen una estructura lineal y continua para la administración y expresión de un transgén. Los vectores de ceADN comprenden un casete de expresión flanqueado por dos secuencias de ITR, donde el casete de expresión codifica un transgén que codifica una proteína FVIII. Algunos vectores de ceADN comprenden además elementos reguladores cis, que incluyen interruptores reguladores. En la presente se proporcionan además métodos y líneas celulares para una expresión génica confiable de la proteína FVIII in vitro, ex vivo e in vivo mediante el uso de los vectores de ceADN. En la presente se proporcionan métodos y composiciones que comprenden vectores de ceADN útiles para la expresión de la proteína FVIII en una célula, tejido o sujeto, y métodos de tratamiento de enfermedades con dichos vectores de ceADN que expresan la proteína FVIII. Tal proteína FVIII se puede expresar para tratar enfermedades, por ejemplo, hemofilia A.
MX2021011039A 2019-03-13 2020-03-13 Vectores de adn no virales y usos de estos para expresar agentes terapéuticos con fviii. MX2021011039A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962817904P 2019-03-13 2019-03-13
US201962856432P 2019-06-03 2019-06-03
PCT/US2020/022738 WO2020186207A2 (en) 2019-03-13 2020-03-13 Non-viral dna vectors and uses thereof for expressing fviii therapeutics

Publications (1)

Publication Number Publication Date
MX2021011039A true MX2021011039A (es) 2021-12-15

Family

ID=72426821

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021011039A MX2021011039A (es) 2019-03-13 2020-03-13 Vectores de adn no virales y usos de estos para expresar agentes terapéuticos con fviii.

Country Status (13)

Country Link
US (1) US20220177545A1 (es)
EP (1) EP3938523A4 (es)
JP (1) JP2022524434A (es)
KR (1) KR20210151785A (es)
CN (1) CN113874513A (es)
AU (1) AU2020234713A1 (es)
BR (1) BR112021017853A2 (es)
CA (1) CA3133255A1 (es)
IL (1) IL286284A (es)
MA (1) MA55313A (es)
MX (1) MX2021011039A (es)
SG (1) SG11202109850SA (es)
WO (1) WO2020186207A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116234917A (zh) 2020-07-27 2023-06-06 安杰瑞姆生物科学公司 Dna分子组合物及其制备方法和使用方法
WO2023135273A2 (en) * 2022-01-14 2023-07-20 Anjarium Biosciences Ag Compositions of dna molecules encoding factor viii, methods of making thereof, and methods of use thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009067548A1 (en) * 2007-11-19 2009-05-28 The Regents Of The University Of California Novel assay for inhibitors of egfr
JP2012525134A (ja) * 2009-04-30 2012-10-22 サイトス バイオテクノロジー アーゲー インフルエンザ赤血球凝集素の組成物とその使用
HRP20231183T1 (hr) * 2013-02-15 2024-01-05 Bioverativ Therapeutics Inc. Optimizirani gen faktora viii
RU2710307C2 (ru) * 2013-09-12 2019-12-26 Байомарин Фармасьютикал Инк. Векторы экспрессии фактора viii на основе аденоассоциированного вируса
GB2526339A (en) * 2014-05-21 2015-11-25 Imp Innovations Ltd Lentiviral vectors
WO2017021359A1 (en) * 2015-08-03 2017-02-09 Myodopa Limited Systemic synthesis and regulation of l-dopa
WO2017074526A1 (en) * 2015-10-28 2017-05-04 Sangamo Biosciences, Inc. Liver-specific constructs, factor viii expression cassettes and methods of use thereof
PE20231949A1 (es) * 2015-10-30 2023-12-05 Spark Therapeutics Inc VARIANTES DEL FACTOR VIII REDUCIDO CON CpG, COMPOSICIONES Y METODOS Y USOS PARA EL TRATAMIENTO DE TRASTORNOS DE LA HEMOSTASIA
SG10201913688TA (en) * 2016-03-03 2020-03-30 Univ Massachusetts Closed-ended linear duplex dna for non-viral gene transfer
PE20181922A1 (es) * 2016-04-15 2018-12-11 Univ Pennsylvania Terapia genica para tratar la hemofilia a
CA3071519A1 (en) * 2017-08-01 2019-02-07 Spark Therapeutics, Inc. Factor viii (fviii) gene therapy methods
US20210163986A1 (en) * 2017-08-09 2021-06-03 Bioverativ Therapeutics Inc. Nucleic acid molecules and uses thereof

Also Published As

Publication number Publication date
EP3938523A2 (en) 2022-01-19
CN113874513A (zh) 2021-12-31
WO2020186207A2 (en) 2020-09-17
CA3133255A1 (en) 2020-09-17
AU2020234713A1 (en) 2021-11-04
US20220177545A1 (en) 2022-06-09
KR20210151785A (ko) 2021-12-14
EP3938523A4 (en) 2023-06-21
BR112021017853A2 (pt) 2021-11-30
IL286284A (en) 2021-10-31
WO2020186207A8 (en) 2020-11-12
SG11202109850SA (en) 2021-10-28
WO2020186207A3 (en) 2020-12-17
MA55313A (fr) 2022-01-19
JP2022524434A (ja) 2022-05-02

Similar Documents

Publication Publication Date Title
PH12020551039A1 (en) Non-viral dna vectors and uses thereof for antibody and fusion protein production
US20200340012A1 (en) Crispr-cas genome engineering via a modular aav delivery system
MX2021011037A (es) Vectores de adn no virales y usos de estos para expresar agentes terapéuticos de fenilalanina hidroxilasa (pah).
CO2018005215A2 (es) Construcciones específicas del hígado para expresión del factor viii
WO2017077329A3 (en) Nucleic acids, peptides and methods
AU2018240515A1 (en) Nucleic acids encoding CRISPR-associated proteins and uses thereof
WO2019191341A8 (en) Nucleic acid-based therapeutics
MX2020006065A (es) Metodos y productos para la produccion y administracion de acido nucleico.
Ni et al. Lentiviral vector-mediated co-overexpression of VEGF and Bcl-2 improves mesenchymal stem cell survival and enhances paracrine effects in vitro
GB0911870D0 (en) Optimised coding sequence and promoter
MX359953B (es) Ácido nucleico que comprende o que codifica un tallo-rizo de histona y una secuencia poli (a) o una señal de poliadenilación para incrementar la expresión de una proteína terapéutica codificada.
MX362028B (es) Polipeptidos recombinantes extendidos y composiciones que comprenden los mismos.
MX2019002345A (es) Moleculas artificiales de acido nucleico para la expresion mejorada de proteina o peptido.
BRPI0510475B8 (pt) adenovírus quimérico recombinante, uso do mesmo no tratamento de câncer e métodos de inibição de crescimento de uma célula de câncer, de fornecimento de uma proteína terapêutica a uma célula e para o isolamento do adenovírus
EP1859046A4 (en) EXPRESSION VECTOR FOR ANIMAL CELL COMPRISING AT LEAST ONE COPY OF MAR MARKER SEQUENCES AT THE 3 'TERMINAL OF THE GENE TRANSCRIPTION TERMINATION REGION AND EXPRESSION TECHNIQUE OF A FOREIGN GENE USING THE SAME
IN2012DN02981A (es)
MX2022011805A (es) Vectores de adn no virales y usos de estos para expresar agentes terapéuticos con factor ix.
MX2021011039A (es) Vectores de adn no virales y usos de estos para expresar agentes terapéuticos con fviii.
WO2022198025A3 (en) Non-viral dna vectors and uses thereof for expressing pfic therapeutics
MX2021009696A (es) Vectores de genoterapia para el tratamiento de la enfermedad de danon.
MX2021006253A (es) Terapias génicas para enfermedad neurodegenerativa.
MX2022005236A (es) Composiciones y metodos para el tratamiento de la perdida auditiva neurosensorial mediante el uso de sistemas de vectores duales de otoferlina.
WO2011028880A3 (en) Methods for enhancing genome stability and telomere elongation in embryonic stem cells
US20240139254A1 (en) Mesenchymal stem cell having oxidative stress resistance, preparation method therefor, and use thereof
MX2022011806A (es) Vectores de adn no virales y usos de estos para expresar agentes terapéuticos contra gaucher.